Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athene Holding Ltd. stock logo
ATH
Athene
$83.33
$82.69
$40.21
$91.26
$16.01B1.691.28 million shs3.50 million shs
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
C$4.74
-2.1%
C$4.56
C$3.70
C$6.20
C$406.31M1.8236,816 shs75,800 shs
MEQ
Mainstreet Equity
$0.00
$0.00
$0.00
N/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.05
$0.05
$0.25
$3.56
$1.37M2.34455,220 shs4 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athene Holding Ltd. stock logo
ATH
Athene
0.00%0.00%0.00%0.00%0.00%
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
-2.07%+4.87%+21.23%-7.78%+10.23%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%-7.00%-4.32%+29.17%-99.26%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athene Holding Ltd. stock logo
ATH
Athene
0.6174 of 5 stars
0.00.00.03.70.01.71.9
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
1.0947 of 5 stars
2.00.01.70.00.61.71.9
MEQ
Mainstreet Equity
N/AN/AN/AN/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athene Holding Ltd. stock logo
ATH
Athene
N/AN/AN/AN/A
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
2.00
HoldC$5.5016.03% Upside
MEQ
Mainstreet Equity
N/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/A

Current Analyst Ratings

Latest OPHR, ATH, SQZ, MEQ, and CFW Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/15/2024
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector PerformC$6.50 ➝ C$5.50
3/15/2024
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
ATB Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector PerformC$10.00 ➝ C$6.00
3/15/2024
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ HoldC$7.00 ➝ C$5.00
3/14/2024
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
Stifel Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athene Holding Ltd. stock logo
ATH
Athene
$14.76B1.08$9.00 per share9.26$105.33 per share0.79
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
C$1.86B0.22C$0.19 per share24.57C$7.18 per share0.66
MEQ
Mainstreet Equity
N/AN/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$18.16M0.08N/AN/A$1.94 per share0.02

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athene Holding Ltd. stock logo
ATH
Athene
$1.54B$18.944.409.09N/A13.69%14.35%1.40%N/A
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
C$197.57MC$2.242.12N/A10.23%38.03%12.22%5/7/2024 (Confirmed)
MEQ
Mainstreet Equity
N/AN/A0.00N/AN/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/A

Latest OPHR, ATH, SQZ, MEQ, and CFW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
-C$0.01N/A+C$0.01N/AN/AN/A
3/14/2024Q4 2023
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
C$0.23C$0.15-C$0.08C$0.16C$402.50 millionC$421.40 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athene Holding Ltd. stock logo
ATH
Athene
N/AN/AN/AN/AN/A
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
C$0.061.27%N/A2.68%N/A
MEQ
Mainstreet Equity
N/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athene Holding Ltd. stock logo
ATH
Athene
0.11
0.65
0.65
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
44.68
2.20
1.33
MEQ
Mainstreet Equity
N/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/A
3.50
3.50

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Athene Holding Ltd. stock logo
ATH
Athene
85.87%
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
20.53%
MEQ
Mainstreet Equity
N/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
38.51%

Insider Ownership

CompanyInsider Ownership
Athene Holding Ltd. stock logo
ATH
Athene
6.80%
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
46.88%
MEQ
Mainstreet Equity
N/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
16.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Athene Holding Ltd. stock logo
ATH
Athene
1,350192.14 million179.08 millionOptionable
Calfrac Well Services Ltd. stock logo
CFW
Calfrac Well Services
2,40085.72 millionN/ANot Optionable
MEQ
Mainstreet Equity
N/AN/AN/ANot Optionable
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
5329.49 million24.77 millionNot Optionable

OPHR, ATH, SQZ, MEQ, and CFW Headlines

SourceHeadline
Reviewing BioAtla (NASDAQ:BCAB) and SQZ Biotechnologies (NYSE:SQZ)Reviewing BioAtla (NASDAQ:BCAB) and SQZ Biotechnologies (NYSE:SQZ)
americanbankingnews.com - April 22 at 1:26 AM
VC funding update: who raised money in March?VC funding update: who raised money in March?
bizjournals.com - April 1 at 11:06 AM
SQZ, Portal founder Armon Sharei on starting over in biotechSQZ, Portal founder Armon Sharei on starting over in biotech
biopharmadive.com - March 26 at 10:35 AM
Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VCPortal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC
finance.yahoo.com - March 19 at 10:20 AM
SQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to StemcellSQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to Stemcell
fiercebiotech.com - March 1 at 10:56 AM
Rx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and moreRx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and more
mmm-online.com - February 16 at 8:05 AM
SQZB SQZ Biotechnologies CompanySQZB SQZ Biotechnologies Company
seekingalpha.com - December 28 at 1:42 PM
SQZ Biotechnologies Co Ordinary Shares SQZBSQZ Biotechnologies Co Ordinary Shares SQZB
morningstar.com - December 12 at 8:37 PM
SQZ founder Armon Sharei opens Portal to to simplify intracellular deliverySQZ founder Armon Sharei opens Portal to to simplify intracellular delivery
fiercebiotech.com - December 12 at 10:35 AM
Medicine at a bigger scale: FUJIFILM Diosynth Biotechnologies unveils new Holly Springs drug manufacturing site'Medicine at a bigger scale': FUJIFILM Diosynth Biotechnologies unveils new Holly Springs drug manufacturing site
wral.com - November 11 at 8:41 PM
‘Difficult but necessary steps’: SQZ lays off 80% of staff, RegenXBio cuts 15%‘Difficult but necessary steps’: SQZ lays off 80% of staff, RegenXBio cuts 15%
fiercebiotech.com - November 9 at 10:34 AM
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio UpdatesSQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
finance.yahoo.com - November 8 at 6:33 PM
SQZ Biotechnologies GAAP EPS of -$0.80 misses by $0.30, revenue of $0MSQZ Biotechnologies GAAP EPS of -$0.80 misses by $0.30, revenue of $0M
msn.com - November 8 at 6:33 PM
Lifeline Biotechnologies Inc LLBOLifeline Biotechnologies Inc LLBO
morningstar.com - November 4 at 11:41 PM
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual MeetingSQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
finance.yahoo.com - November 3 at 7:42 PM
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio UpdatesSQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
finance.yahoo.com - August 10 at 9:16 PM
Sqz Biotechnologies Co (SQZB)Sqz Biotechnologies Co (SQZB)
investing.com - August 3 at 7:45 AM
Roche declines to take up option on SQZ Bio’s SQZ-APC-HPV programRoche declines to take up option on SQZ Bio’s SQZ-APC-HPV program
thepharmaletter.com - July 27 at 12:11 AM
Roche Passes on Option to Advance Cell Therapy in HPV-Positive Tumors With SQZ BiotechnologiesRoche Passes on Option to Advance Cell Therapy in HPV-Positive Tumors With SQZ Biotechnologies
precisionmedicineonline.com - July 25 at 10:53 PM
Roche Decides Not to Exercise Solid Tumor Option with SQZRoche Decides Not to Exercise Solid Tumor Option with SQZ
biospace.com - July 25 at 10:53 PM
SQZ Biotechnologies Provides Update on Collaboration with RocheSQZ Biotechnologies Provides Update on Collaboration with Roche
benzinga.com - July 25 at 12:37 PM
Roche snubs SQZ HPV 16 programme, leaving the beleaguered company in the lurchRoche snubs SQZ HPV 16 programme, leaving the beleaguered company in the lurch
pharmaceutical-technology.com - July 25 at 12:37 PM
Understanding the Risks of Investing in SQZ Biotechnologies Company (SQZ)Understanding the Risks of Investing in SQZ Biotechnologies Company (SQZ)
knoxdaily.com - July 5 at 1:10 PM
SQZ Biotechnologies to be delisted from the NYSESQZ Biotechnologies to be delisted from the NYSE
seekingalpha.com - July 3 at 11:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Athene logo

Athene

NYSE:ATH
Athene Holding Ltd. is engages in the provision of retirement services. The firm issues, reinsures and acquires retirement savings products and institutional products. It operates through following segments: Retirement Services, and Corporate and Other. The Retirement Services segment is comprised of US and Bermuda operations, which issue and reinsure retirement savings products and institutional products. The Corporate and Other segment includes corporate activities such as corporate allocated expenses, merger and acquisition costs, debt costs, preferred stock dividends, certain integration and restructuring costs, certain stock-based compensation and intersegment eliminations. The company was founded by James R. Belardi and Frank L. Gills in May 2009 and is headquartered in Pembroke, Bermuda.
Calfrac Well Services logo

Calfrac Well Services

TSE:CFW
Calfrac Well Services Ltd., together with its subsidiaries, provides specialized oilfield services in Canada, the United States, and Argentina. It offers hydraulic fracturing, coiled tubing, cementing, and other well completion services for the oil and natural gas industry. The company was founded in 1999 and is headquartered in Calgary, Canada.

Mainstreet Equity

NYSE:MEQ
SQZ Biotechnologies logo

SQZ Biotechnologies

NYSE:SQZ
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.